Compounded GLP-1/GIP (Tirzepatide)
US$ 24.71
tirzepatide and memory problems Problems: What the Evidence Shows π§ Let's break the drug tirzepatide
Description
Personal and family health history, weight loss and health goals, side effects, access, and cost are some of the factors clinicians consider when prescribing one of these medications
There is ongoing concern about the weight loss that comes from lean mass
How the dose is escalated is highly individual
In clinical trials, about 25% to 29% of people taking Zepbound experienced nausea, compared to only 8% taking a placebo
One example is a triple agonist (GLP1/GIP/glucagon receptor agonist) currently in Phase 2 and 3 trials
Zepbound is FDA-approved for weight loss in people without diabetes
